KRAS and neoplasm: Our study extends the current paradigm to imply that patients with KRAS-, BRAF- or PIK3CA-mutant tumours may all derive limited benefit from treatment with EGFR mAb, and that BRAF mutations in particular account for a measurable fraction of patients whose KRASWT tumours do not respond to cetuximab.